liu.seSearch for publications in DiVA
Change search
Link to record
Permanent link

Direct link
Publications (8 of 8) Show all publications
Marking, U., Bladh, O., Aguilera, K., Yang, Y., Greilert Norin, N., Blom, K., . . . Thålin, C. (2024). Humoral immune responses to the monovalent XBB.1.5-adapted BNT162b2 mRNA booster in Sweden [Letter to the editor]. The Lancet - Infectious diseases, 24(2), e80-e81
Open this publication in new window or tab >>Humoral immune responses to the monovalent XBB.1.5-adapted BNT162b2 mRNA booster in Sweden
Show others...
2024 (English)In: The Lancet - Infectious diseases, ISSN 1473-3099, E-ISSN 1474-4457, Vol. 24, no 2, p. e80-e81Article in journal, Letter (Refereed) Published
Abstract [en]

Conflict of interest statement

pCMV-dR8·2 dvpr was a gift from Bob Weinberg (Addgene plasmid # 8455; http://n2t.net/addgene:8455; RRID:Addgene_8455). pBOBI-FLuc was a gift from David Nemazee (Addgene plasmid # 170674; http://n2t.net/addgene:170674; RRID: Addgene_170674). We acknowledge the G2P-UK National Virology consortium funded by MRC/UKRI (grant ref: MR/W005611/1) and the Barclay Lab at Imperial College for providing the XBB.1.5 spike plasmid. We gratefully acknowledge all data contributors, ie, the authors and their originating laboratories responsible for obtaining the specimens, and their submitting laboratories that generated the genetic sequence and metadata and shared via the GISAID Initiative the data on which part of this research is based. This project was supported by funding from the Jonas and Christina af Jochnick Foundation, Region Stockholm, SciLifeLab/Knut and Alice Wallenberg Foundation, SciLifeLab's Pandemic Laboratory Preparedness program (VC-2022–0028) and from the Erling Persson Foundation (2021 0125). DJS has served as a consultant for AstraZeneca outside this comment. All other authors declare no competing interests. UM and OB contributed equally and share first authorship; DJS and CT jointly supervised the work and share last authorship.

Place, publisher, year, edition, pages
Elsevier, 2024
National Category
Immunology in the Medical Area
Identifiers
urn:nbn:se:liu:diva-212909 (URN)10.1016/s1473-3099(23)00779-x (DOI)001178078500001 ()38190833 (PubMedID)2-s2.0-85182978994 (Scopus ID)
Funder
Knut and Alice Wallenberg FoundationStockholm County CouncilScience for Life Laboratory, SciLifeLabFamiljen Erling-Perssons Stiftelse
Available from: 2025-04-09 Created: 2025-04-09 Last updated: 2025-08-18
Bacchus, P., Christ, W., Frisell, A., Greilert-Norin, N., Marking, U., Havervall, S., . . . Groenheit, R. (2024). Logistics for Rapid Isolation of Viruses From Humans. HEALTH SECURITY, 22(5), 394-397
Open this publication in new window or tab >>Logistics for Rapid Isolation of Viruses From Humans
Show others...
2024 (English)In: HEALTH SECURITY, ISSN 2326-5094, Vol. 22, no 5, p. 394-397Article in journal (Refereed) Published
Abstract [en]

An important aspect of microbiological surveillance is the ability to access to live viruses for microneutralization assays, which enables the study of viral characteristics and mechanisms in vitro and production of positive controls for diagnostic methods. During the COVID-19 pandemic, the Public Health Agency of Sweden established a protocol for the rapid collection of clinical samples and subsequent isolation of novel virus variants.

Place, publisher, year, edition, pages
MARY ANN LIEBERT, INC, 2024
Keywords
SARS-CoV-2; Epidemic management/response; Public health preparedness/response; Surveillance; Early response; Omicron
National Category
Microbiology in the medical area
Identifiers
urn:nbn:se:liu:diva-207915 (URN)10.1089/hs.2023.0146 (DOI)001314496300001 ()
Available from: 2024-10-01 Created: 2024-10-01 Last updated: 2024-11-19Bibliographically approved
Kuhn, J. H., Abe, J., Adkins, S., Alkhovsky, S. V., Avšič-Županc, T., Ayllón, M. A., . . . Klingström, J. (2023). Annual (2023) taxonomic update of RNA-directed RNA polymerase-encoding negative-sense RNA viruses (realm Riboviria: kingdom Orthornavirae: phylum Negarnaviricota) [Letter to the editor]. Journal of General Virology, 104(8)
Open this publication in new window or tab >>Annual (2023) taxonomic update of RNA-directed RNA polymerase-encoding negative-sense RNA viruses (realm Riboviria: kingdom Orthornavirae: phylum Negarnaviricota)
Show others...
2023 (English)In: Journal of General Virology, ISSN 0022-1317, E-ISSN 1465-2099, Vol. 104, no 8Article in journal, Letter (Other academic) Published
Abstract [en]

In April 2023, following the annual International Committee on Taxonomy of Viruses (ICTV) ratification vote on newly proposed taxa, the phylum Negarnaviricota was amended and emended. The phylum was expanded by one new family, 14 new genera, and 140 new species. Two genera and 538 species were renamed. One species was moved, and four were abolished. This article presents the updated taxonomy of Negarnaviricota as now accepted by the ICTV.

Place, publisher, year, edition, pages
Microbiology Society, 2023
Keywords
Aliusviridae; Arenaviridae; Articulavirales; Artoviridae; Aspiviridae; Bornaviridae; Bunyavirales; Crepuscuviridae; Discoviridae; Filoviridae; Fimoviridae; Goujianvirales; Hantaviridae; ICTV; International Committee on Taxonomy of Viruses; Jingchuvirales; Lispiviridae; Mononegavirales; Muvirales; Mymonaviridae; Myriaviridae; Nairoviridae; Natareviridae; Negarnaviricota; Nyamiviridae; Orthomyxoviridae; Orthornavirae; Paramyxoviridae; Peribunyaviridae; Phasmaviridae; Phenuiviridae; Pneumoviridae; Rhabdoviridae; Riboviria; Serpentovirales; Sunviridae; Tenuivirus; Tosoviridae; Tospoviridae; Tulasviridae; articulaviral; bunyaviral; bunyavirus; goujianviral; megaclassification; megataxonomy; mononegaviral; muviral; negarnaviricot; serpentoviral; virus classification; virus nomenclature; virus taxonomy
National Category
Microbiology Zoology Botany
Identifiers
urn:nbn:se:liu:diva-201902 (URN)10.1099/jgv.0.001864 (DOI)001162856800001 ()37622664 (PubMedID)
Available from: 2024-03-26 Created: 2024-03-26 Last updated: 2024-04-29
Marking, U., Havervall, S., Norin, N. G., Bladh, O., Christ, W., Gordon, M., . . . Thålin, C. (2023). Correlates of protection and viral load trajectories in omicron breakthrough infections in triple vaccinated healthcare workers. Nature Communications, 14(1), Article ID 1577.
Open this publication in new window or tab >>Correlates of protection and viral load trajectories in omicron breakthrough infections in triple vaccinated healthcare workers
Show others...
2023 (English)In: Nature Communications, E-ISSN 2041-1723, Vol. 14, no 1, article id 1577Article in journal (Refereed) Published
Abstract [en]

Vaccination offers protection against severe COVID-19 caused by SARS-CoV-2 omicron but is less effective against infection. Characteristics such as serum antibody titer correlation to protection, viral abundance and clearance of omicron infection in vaccinated individuals are scarce. We present a 4-week twice-weekly SARS-CoV-2 qPCR screening in 368 triple vaccinated healthcare workers. Spike-specific IgG levels, neutralization titers and mucosal spike-specific IgA-levels were determined at study start and qPCR-positive participants were sampled repeatedly for two weeks. 81 (cumulative incidence 22%) BA.1, BA.1.1 and BA.2 infections were detected. High serum antibody titers are shown to be protective against infection (p < 0.01), linked to reduced viral load (p < 0.01) and time to viral clearance (p < 0.05). Pre-omicron SARS-CoV-2 infection is independently associated to increased protection against omicron, largely mediated by mucosal spike specific IgA responses (nested models lr test p = 0.02 and 0.008). Only 10% of infected participants remain asymptomatic through the course of their infection. We demonstrate that high levels of vaccine-induced spike-specific WT antibodies are linked to increased protection against infection and to reduced viral load if infected, and suggest that the additional protection offered by pre-omicron SARS-CoV-2 infection largely is mediated by mucosal spike-specific IgA.

Place, publisher, year, edition, pages
Springer Nature, 2023
National Category
Infectious Medicine
Identifiers
urn:nbn:se:liu:diva-197733 (URN)10.1038/s41467-023-36984-1 (DOI)001063479500004 ()36949041 (PubMedID)
Funder
Stockholm County CouncilScience for Life Laboratory, SciLifeLabFamiljen Erling-Perssons StiftelseSwedish Research Council
Note

Funding: Jonas and Christina af Jocknick Foundation; Region Stockholm; SciLifeLab; Knut and Alice Wallenberg Foundation; Leif Lundblad Family Foundation; Erling-Persson family foundation; Swedish Research Council; Swedish Heart and Lung Foundation; Bill & Melinda Gates Foundation; Center for Innovative Medicine

Available from: 2023-09-12 Created: 2023-09-12 Last updated: 2023-10-11Bibliographically approved
Vial, P. A., Ferrés, M., Vial, C., Klingström, J., Ahlm, C., López, R., . . . Mertz, G. J. (2023). Hantavirus in humans: a review of clinical aspects and management. The Lancet - Infectious diseases, 23(9), e371-e382
Open this publication in new window or tab >>Hantavirus in humans: a review of clinical aspects and management
Show others...
2023 (English)In: The Lancet - Infectious diseases, ISSN 1473-3099, E-ISSN 1474-4457, Vol. 23, no 9, p. e371-e382Article, review/survey (Refereed) Published
Abstract [en]

Hantavirus infections are part of the broad group of viral haemorrhagic fevers. They are also recognised as a distinct model of an emergent zoonotic infection with a global distribution. Many factors influence their epidemiology and transmission, such as climate, environment, social development, ecology of rodent hosts, and human behaviour in endemic regions. Transmission to humans occurs by exposure to infected rodents in endemic areas; however, Andes hantavirus is unique in that it can be transmitted from person to person. As hantaviruses target endothelial cells, they can affect diverse organ systems; increased vascular permeability is central to pathogenesis. The main clinical syndromes associated with hantaviruses are haemorrhagic fever with renal syndrome (HFRS), which is endemic in Europe and Asia, and hantavirus cardiopulmonary syndrome (HCPS), which is endemic in the Americas. HCPS and HFRS are separate clinical entities, but they share several features and have many overlapping symptoms, signs, and pathogenic alterations. For HCPS in particular, clinical outcomes are highly associated with early clinical suspicion, access to rapid diagnostic testing or algorithms for presumptive diagnosis, and prompt transfer to a facility with critical care units. No specific effective antiviral treatment is available.

Place, publisher, year, edition, pages
Elsevier, 2023
National Category
Infectious Medicine
Identifiers
urn:nbn:se:liu:diva-197730 (URN)10.1016/s1473-3099(23)00128-7 (DOI)001072260600001 ()37105214 (PubMedID)
Note

Funding: NIH [U01 AI045452]; Fondecyt [1211825, 1201240, ATE220061]; Center for Medical Innovation [20200141]

Available from: 2023-09-12 Created: 2023-09-12 Last updated: 2024-01-17Bibliographically approved
Bladh, O., Marking, U., Havervall, S., Norin, N. G., Aguilera, K., Hober, S., . . . Thålin, C. (2023). Mucosal immune responses following a fourth SARS-CoV-2 vaccine dose [Letter to the editor]. The Lancet Microbe, 4(7), e488-e488
Open this publication in new window or tab >>Mucosal immune responses following a fourth SARS-CoV-2 vaccine dose
Show others...
2023 (English)In: The Lancet Microbe, ISSN 2666-5247, Vol. 4, no 7, p. e488-e488Article in journal, Letter (Refereed) Published
Place, publisher, year, edition, pages
Elsevier, 2023
National Category
Infectious Medicine
Identifiers
urn:nbn:se:liu:diva-197732 (URN)10.1016/s2666-5247(23)00102-7 (DOI)001095634800001 ()37086736 (PubMedID)
Note

Supplementary appendix

This appendix formed part of the original submission. We post it as supplied by the authors. Supplement to: Bladh O, Marking U, Havervall S, et al. Mucosal immune responses following a fourth SARS-CoV-2 vaccine dose. Lancet Microbe 2023; published online April 19. https://doi.org/10.1016/S2666-5247(23)00102-7

Available from: 2023-09-12 Created: 2023-09-12 Last updated: 2025-12-22Bibliographically approved
Groenheit, R., Galanis, I., Sonden, K., Sperk, M., Movert, E., Bacchus, P., . . . Blom, K. (2023). Rapid emergence of omicron sublineages expressing spike protein R346T [Letter to the editor]. The Lancet Regional Health: Europe, 24, Article ID 100564.
Open this publication in new window or tab >>Rapid emergence of omicron sublineages expressing spike protein R346T
Show others...
2023 (English)In: The Lancet Regional Health: Europe, E-ISSN 2666-7762, Vol. 24, article id 100564Article in journal, Letter (Refereed) Published
Place, publisher, year, edition, pages
ELSEVIER, 2023
National Category
Infectious Medicine
Identifiers
urn:nbn:se:liu:diva-191377 (URN)10.1016/j.lanepe.2022.100564 (DOI)000904091200004 ()36533118 (PubMedID)
Available from: 2023-02-01 Created: 2023-02-01 Last updated: 2024-04-09
Vikström, L., Fjällström, P., Gwon, Y.-D., Sheward, D. J., Wigren-Byström, J., Evander, M., . . . Forsell, M. N. .. (2023). Vaccine-induced correlate of protection against fatal COVID-19 in older and frail adults during waves of neutralization-resistant variants of concern: an observational study. The Lancet Regional Health - Europe, 30, 100646-100646, Article ID 100646.
Open this publication in new window or tab >>Vaccine-induced correlate of protection against fatal COVID-19 in older and frail adults during waves of neutralization-resistant variants of concern: an observational study
Show others...
2023 (English)In: The Lancet Regional Health - Europe, ISSN 2666-7762, Vol. 30, p. 100646-100646, article id 100646Article in journal (Refereed) Published
Abstract [en]

Background: To inform future preventive measures including repeated vaccinations, we have searched for a clinically useful immune correlate of protection against fatal COVID-19 among nursing homes residents.

Methods: We performed repeated capillary blood sampling with analysis of S-binding IgG in an open cohort of nursing home residents in Sweden. We analyzed immunological and registry data from 16 September 2021 to 31 August 2022 with follow-up of deaths to 30 September 2022. The study period included implementation of the 3rd and 4th mRNA monovalent vaccine doses and Omicron virus waves.

Findings: A total of 3012 nursing home residents with median age 86 were enrolled. The 3rd mRNA dose elicited a 99-fold relative increase of S-binding IgG in blood and corresponding increase of neutralizing antibodies. The 4th mRNA vaccine dose boosted levels 3.8-fold. Half-life of S-binding IgG was 72 days. A total 528 residents acquired their first SARS-CoV-2 infection after the 3rd or the 4th vaccine dose and the associated 30-day mortality was 9.1%. We found no indication that levels of vaccine-induced antibodies protected against infection with Omicron VOCs. In contrast, the risk of death was inversely correlated to levels of S-directed IgG below the 20th percentile. The death risk plateaued at population average above the lower 35th percentile of S-binding IgG.

Interpretation: In the absence of neutralizing antibodies that protect from infection, quantification of S-binding IgG post vaccination may be useful to identify the most vulnerable for fatal COVID-19 among the oldest and frailest. This information is of importance for future strategies to protect vulnerable populations against neutralization resistant variants of concern.

Place, publisher, year, edition, pages
Elsevier, 2023
Keywords
COVID-19; Correlate of protection; Immune monitoring of vulnerable populations; Longevity of vaccination; Open cohort study; Vaccination; Vulnerable population
National Category
Infectious Medicine
Identifiers
urn:nbn:se:liu:diva-212910 (URN)10.1016/j.lanepe.2023.100646 (DOI)37363799 (PubMedID)2-s2.0-85156247971 (Scopus ID)
Available from: 2025-04-09 Created: 2025-04-09 Last updated: 2025-06-03Bibliographically approved
Organisations
Identifiers
ORCID iD: ORCID iD iconorcid.org/0000-0001-9076-1441

Search in DiVA

Show all publications